Skip to main content

RAD December 2021 Conference Abstracts and Posters

All accepted abstracts will be published in the British Journal of Dermatology.

599 - Dupilumab Monotherapy Provides 1 Year Sustained Response in Adults With Moderate-to-Severe Atopic Dermatitis Optimally Responding at Week 16, With no Need of Concomitant Topical Steroids

Margitta Worm, Eric L. Simpson, Diamant Thaçi, Lisa A. Beck, Amy Praestgaard, Genevieve Wortzman-Show, Ana B. Rossi


600 - Clinically meaningful improvements in patient-reported outcomes and itch: analysis of a phase 2 clinical trial in adults with moderate to severe atopic dermatitis treated with etrasimod, a novel, oral selective sphingosine 1-phosphate receptor modulator

Dedee F. Murrell, Emma Guttman-Yassky, Robert Bissonnette, Leon Kircik, Andrew Selfridge, Kris Liu, Gurpreet Ahluwalia, Jonathan I. Silverberg


602 - Systematic development of pro- and pre-biotic treatments for atopic dermatitis.

Ian A Myles, MD/MPH


604 - Efficacy and Safety of Switching from Dupilumab to Upadacitinib in Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label Extension Trial

Andrew Blauvelt, Barry Ladizinski, Vimal H. Prajapati, Vivian Laquer, Alison Fischer, Samantha Eisman, Tianshuang Wu, Namita Vigna, Henrique D. Teixeira, John Liu, Kilian Eyerich


605 - Safety and Effectiveness of Dupilumab in the Treatment of Atopic Dermatitis in Japanese Patients: The First Interim Analysis Report From Post-Marketing Surveillance

Hiroyuki Fujita, Katsuhisa Suzuki, Kazuhiko Arima


611 - EASI Data Visualization: A New Interactive Tool to Evaluate the Efficacy of Drugs by EASI Clinical Sign and Body Region Using Example Data from a Phase 2b Study of Lebrikizumab in Atopic Dermatitis

Jonathan I. Silverberg, (Presenter) Peter A. Lio, David Rosmarin, Luna Sun, Maria Jose Rueda, Deepak Krishna Lola


615 - Two-year Maintenance of Response with Tralokinumab in Moderate-to-Severe Atopic Dermatitis: Interim Analysis of the ECZTEND Open-Label Extension Trial

Andrew Blauvelt, Jean-Philippe Lacour, Darryl Toth, Richard Langley, Richard Warren, Pedro Herranz Pinto, Andrew Pink, Eric Simpson, Ketty Peris, Andreas Wollenberg, Le Gjerum, Stine Fangel, Josh Corriveau, Shannon Schneider, Kristian Reich


617 - Updates on COVID-19 cases and SARS-CoV-2 vaccinations during tralokinumab treatment in moderate-to-severe atopic dermatitis from ECZTEND long-term extension trial

Richard Langley, Andrew Pink, Margitta Worm, Antonio Costanzo, Le Gjerum, Emilie Jorgensen, Joshua Corriveau, Shannon Schneider, Emma Guttman-Yassky, Andrew Blauvelt


618 - CONTENT VALIDITY AND ASSESSMENT OF THE PSYCHOMETRIC PROPERTIES AND SCORE INTERPRETATION OF A PRURITUS NUMERIC RATING SCALE SCORE IN ATOPIC DERMATITIS AUTHORS AND AFFILIATIONS:

Gil Yosipovitch, Alissa Rams, Jessica Baldasaro, Laurine Bunod, Laure Delbecque, Sara Strzok, Juliette Meunier, Hany Elmaraghy, Luna Sun, Evangeline Pierce


619 - Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial

Amy Paller, Andrew Blauvelt, Weily Soong, Shinichi Imafuku, Chih-ho Hong, Marie L.A. Schuttelaar, Petra Amoudruz, Azra Kurbasic, Lise Soldbro, Katja Lophaven, Shannon Schneider, Michael Cork, Anthony Bewley, Eric L. Simpson


Page 2 of 7
Results 11 - 20 of 66